Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line therapy for extensive-stage small–cell lung cancer (ES-SCLC): a phase II trial

Chen, Dawei; Zou, Bing; Li, Butuo; Gao, Aiqin; Huang, Wei; Shao, Qian; Meng, Xiangjiao; Zhang, Pinliang; Tang, Xiaoyong; Hu, Xudong; Zhang, Yan; Guo, Jun; Zhao, Changhong; Yuan, Jiajia; Li, Qian; Zhu, Changbin; Yu, Jinming; Wang, Linlin

doi:10.1016/j.eclinm.2024.102795

eClinicalMedicine

2024

DOI: 10.1016/j.eclinm.2024.102795

|View full text |Cite

Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line therapy for extensive-stage small–cell lung cancer (ES-SCLC): a phase II trial

Dawei Chen,

Bing Zou,

Butuo Li

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Recent advances in immunotherapy for small cell lung cancer

Ren,

Shang,

Chen

2024

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of review This review aims to provide an overview of recent advances in immunotherapy for small cell lung cancer (SCLC), with a focus on the current status of immune checkpoint inhibitors (ICIs), novel combination strategies, and key biomarkers. Recent findings The integration of ICIs into standard chemotherapy has established them as the first-line treatment for extensive-stage SCLC (ES-SCLC). The ADRIATIC trial further demonstrated the efficacy of ICI maintenance therapy in limited-stage SCLC. Additionally, combining radiotherapy with ICIs has shown promising synergistic effects, including the abscopal and radscopal effects. Ongoing investigations into the combination of ICIs with targeted therapies, such as antiangiogenic agents and DNA damage response inhibitors, have yielded encouraging preliminary results. Notably, the novel therapeutic agent tarlatamab, the first bispecific DLL3-directed CD3 T-cell engager, has recently received FDA approval for second-line treatment of ES-SCLC. Advances in omics technologies have shed light on the intra-tumor and inter-tumor heterogeneity of SCLC, leading to the identification of new molecular subtypes and biomarkers, thereby paving the way for precision medicine. Summary Despite the improved outcomes associated with immunotherapy in SCLC, the overall clinical benefit remains modest. Further preclinical and clinical studies are essential to identify optimal treatment regimens and enhance therapeutic efficacy.

show abstract

Recent advances in immunotherapy for small cell lung cancer

Ren,

Shang,

Chen

2024

Current Opinion in Oncology

View full text Add to dashboard Cite

show abstract

Determining optimal clinical target volume margins based on microscopic extracapsular extension of metastatic nodes in patients with non-small-cell lung cancer after chemotherapy or chemotherapy combined with immunotherapy

Zhang,

Li,

Song

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Progress of research on PD-L1 inhibitor adebrelimab usage in malignant tumors

Cheng,

He,

Cheng

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Adebrelimab is a humanized monoclonal antibody against programmed death-ligand 1 (PD-L1) and is also a novel immune checkpoint inhibitor, which has been used in the first-line treatment of extensive stage small cell lung cancer (SCLC) with its unique mechanism of action and good clinical efficacy. Significant progress has been made in the treatment of adebrelimab in other malignancies such as non-small cell lung cancer, triple-negative breast cancer, esophageal squamous cell carcinoma, and the treatment of SCLC at different stages is also being explored. Therefore, adebrelimab emerges as a promising new treatment option for patients with small cell lung cancer (SCLC) and other types of malignant tumors.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line therapy for extensive-stage small–cell lung cancer (ES-SCLC): a phase II trial

Cited by 3 publications

References 46 publications

Recent advances in immunotherapy for small cell lung cancer

Recent advances in immunotherapy for small cell lung cancer

Determining optimal clinical target volume margins based on microscopic extracapsular extension of metastatic nodes in patients with non-small-cell lung cancer after chemotherapy or chemotherapy combined with immunotherapy

Progress of research on PD-L1 inhibitor adebrelimab usage in malignant tumors

Contact Info

Product

Resources

About